restrict the use of Rezulin (troglitazone) for diabetes
May 1999
The FDA may further restrict the use of Rezulin (troglitazone) for diabetes...due to the risk of liver toxicity.
FDA advisors recommend NOT using Rezulin for monotherapy.
They also want the FDA to require patient package inserts...to explain the need for frequent liver function tests.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote